4 Recent SR9009 Case Studies, Their Findings, and Where to Buy SR9009

4 Recent SR9009 Case Studies
Table of Contents

SR 9009 Introduction

Over recent years there has been a lot of discussion surrounding SARMs like SR 9009. These discussions have often been spurred by case studies and laboratory research looking at the effects of SR 9009.

SR 9009 studies are opening many doors to new discoveries. If you’re looking to conduct research, it’s important to do a literature review beforehand. 

Keep reading this guide for recent case studies that have looked at this selective androgen receptor modulator (SARM). 

One: Lung Cancer

For research purposes, a recent study tested SR 9009 and its effects on targeting small cell lung cancer (SCLC Cells). This study posited that the circadian rhythm coordinates cell proliferation and metabolism, which can impact how some diseases progress [1].

Because of this, researchers wanted to see if pharmacological modulation of the circadian rhythm could potentially be an effective way to help treat cancer [1].

The Basics

 For this study, chemosensitive cells and their corresponding chemoresistant cells consisted of the following  [1]:

  • H69
  • H446
  • H69AR
  • H446DDP

The cells were used to look at whether the REV ERBA SR 9009 aided in the treatment of small-cell lung cancer in vitro [1].

The Results and Conclusions

The great results of the study showed that the REV ERBA SR 9009 was lethal to chemoresistant and chemosensitive SCLC cells. There was an antitumor effect that REV-ERBα was involved in [1].

REV-ERBα targeted the core autophagy gene Atg5, and this gene was suppressed by REV ERB agonists SR 9009. In addition, the interaction of REV-ERBα with the Atg5 caused impairment to autophagy activity. This led to SR 9009 cytotoxicity in the small cell lung cancer cells [1].

The conclusions drawn by researchers because of the results of this study state that the REV ERB agonists SR 9009 has the potential to be a novel and promising treatment strategy for the first or second line of small cell lung cancer, but more research must be conducted to verify these results [1].

Two: Alzheimer’s Disease

The next case study discussed involves Alzheimer’s disease. The study shared how there are a lack of treatments that can reverse the pathology and cognitive deficits that occur in subjects with Alzheimer’s [2].

In mouse models, reduced cognitive function gets associated with a loss of function in the nuclear REV ERB receptors. Because the effect of enhancing REV-ERB function on cognitive function hasn’t been examined, this study did so [2].

The Basics

The purpose of this particular study was to test a hypothesis that enhancing REV-ERB function could also enhance cognitive function in a model of Alzheimer’s [2].

The study used 72 treated mice and divided them into three groups. These consisted of [2]:

  • Four-month-old mice getting vehicle (Y-V) 
  • 12-month-old mice getting vehicle (O-V) 
  • 12-month-old mice getting SR9009

All mice treated underwent three behavioral tests to explore how they responded to the study. The behavioral tests consisted of novel object recognition, lever press operant conditioning, and T-maze foot shock avoidance [2].

The Results and Conclusions

During the novel object recognition time task, a reduced amount of time spent exploring a novel object was connected with reduced cognitive function. This is because the natural tendency of mice is to explore new aspects of the environment they’re in [2].

 The O-V mice showed a reduced cognitive function when comparing them to the Y-V mice. But, in almost every case, the SR9009 stenabolic testing showed a cognitive function that was improved significantly. Researchers stated that in many cases, the cognitive function in the SR9009 stenabolic group was not distinguishable from the younger mice [2].

For the T-maze foot shock avoidance task, the group of mice undergoing SR9009 stenabolic testing had significantly improved retention. However, the effect on acquisition was not as pronounced in this group [2].

The third task, lever press reward conditioning, also showed that mice receiving the SR 9009 testing had improved performance. Because of the results of the three tasks, researchers concluded that SR 9009 testing can improve cognitive function in a mouse model of Alzheimer’s disease [2]. 

They also concluded that it’s possible that REV-ERB could possibly be a method utilized to treat Alzheimer’s and other cognitive disorders [2]. In the future, control groups should be utilized to further validate results findings.

Three: Cell Proliferation and Metabolism

The final study we will look at for today involved the independent REV-ERB effects SR 9009 has on cell proliferation and metabolism. This study noted the fact that there have been many reported effects of SR 9009 when utilized in animal studies with cell systems and health or diseased animal models [3]. 

But, researchers have failed to thoroughly assess the direct involvement of REV-ERBs in the effects of SR 9009 [3]. 

For this study, researchers used a conditional REV-ERBα/β double-deletion mouse model. They tested the specificity of SR 9009 and a related compound [3]. 

The Results and Conclusions

In completing this study, researchers found that SR9009 can exert REV-ERB independent effects on metabolism, proliferation, and gene transcription. It can do this in two different cell types depleted of REV-ERBs [3]. 

Because of this, researchers have concluded that the effects of SR 9009 can’t only get attributed to actions on REV-ERBs. The researchers believe that this information is important for anyone using SR 9009 for research on treatment methods for various diseases [3]. 

How this product affects lipid and glucose metabolism should further be studied by researchers. A possible model can be to utilize diet-induced obese mice as test subjects [3]. 

Four: Diet-Induced Obese Mice Leading the Way

The involvement of the circadian rhythms in the development of nonalcoholic steatohepatitis (NASH) has been well-established, as many potential NASH drugs target pathways regulated by the circadian clock. However, the current consideration of chronopharmacology in NASH is limited [4].

The study expressed how, “SR9009 treatment reduces fat content and significantly
improves dyslipidemia and hyperglycemia in diet-induced obese mice”. A recent study aimed to explore the time-dependent effects of the REV-ERBα agonist SR9009 on diet-induced NASH and the microbiota
[4].

In this experiment, C57BL/6J mice were subjected to a high cholesterol and high fat diet (CL) for 12 weeks to induce NASH. Subsequently, the mice were treated with SR9009 either at Zeitgeber time 0 (ZT0) or ZT12 for an additional 6 weeks [4].

The pharmacological activation of REV-ERBα by SR9009 stenabolic demonstrated positive outcomes in CL diet-induced NASH mice, including the alleviation of hepatic steatosis, insulin resistance, liver inflammation, and fibrosis [4]. 

Notably, these beneficial effects were accompanied by improvements in gut barrier function and alterations in microbial composition and function in NASH mice. The effects appeared to be more pronounced when SR9009 was administered at ZT0 [4]. Blood cholesterol levels were not tested in the subjects.

Furthermore, the administration of SR9009 stenabolic at different time points resulted in significant differences in the microbiota composition, with a stronger impact on the enrichment of beneficial bacteria and reduction of harmful bacteria when SR9009 stenabolic was administered at ZT0 [4].
 
Consequently, the time-dependent effects of the REV-ERBα agonist on NASH partially relied on the microbiota, shedding light on the potential involvement of the microbiota in the chronopharmacology of NASH and the exploration of novel therapeutic approaches for this condition [4]. 

How this product affects lipid and glucose metabolism should further be studied by researchers as this, too, was not tested. This is covered further in our stenabolic review.

Buy SR9009 for Your Research

There are still many scientific studies on SR 9009 that need to be completed to understand how it could help in a variety of diseases such as testing genetically modified mice and their effects on the circadian rhythm. For a more in-depth guide on SR9009, check out our Ultimate SR9009 Guide.

However, researchers are still studying the effects of SR 9009 as this compound is only for laboratory research use only such as research conducted by Scripps Research Institute.

Make sure you’re keeping up on the research, and when you’re ready to start your own research, know that we’re here for you. Sports Technology Labs has the high-quality SR9009 for sale for you to supplement your research. 

If you are looking to find the best place for SR9009 for sale, Contact us today. We e would love to discuss your SARMs needs with you.

Note: These chemical compounds are for laboratory purposes only and are not for human consumption.

Scientific References:

1. Shen, W., Zhang, W., Ye, W., Wang, H., Zhang, Q., Shen, J., … & Zhang, J. (2020). SR9009 induces a REV-ERB dependent anti-small-cell lung cancer effect through inhibition of autophagy. Theranostics10(10), 4466.

2. Roby, D. A., Ruiz, F., Kermath, B. A., Voorhees, J. R., Niehoff, M., Zhang, J., … & Burris, T. P. (2019). Pharmacological activation of the nuclear receptor REV-ERB reverses cognitive deficits and reduces amyloid-β burden in a mouse model of Alzheimer’s disease. PLoS One14(4), e0215004.

3. Dierickx, P., Emmett, M. J., Jiang, C., Uehara, K., Liu, M., Adlanmerini, M., & Lazar, M. A. (2019). SR9009 has REV-ERB–independent effects on cell proliferation and metabolism. Proceedings of the National Academy of Sciences116(25), 12147-12152.

4. Ni, Y., Nan, S., Zheng, L., Zhang, L., Zhao, Y., & Fu, Z. (2023). Time-dependent effect of REV-ERBα agonist SR9009 on nonalcoholic steatohepatitis and gut microbiota in mice. Chronobiology International, 1-14.

IT Support by SADOSSecure, Fast Hosting for WordPress